PL377056A1 - New antitumoral compounds - Google Patents

New antitumoral compounds

Info

Publication number
PL377056A1
PL377056A1 PL377056A PL37705603A PL377056A1 PL 377056 A1 PL377056 A1 PL 377056A1 PL 377056 A PL377056 A PL 377056A PL 37705603 A PL37705603 A PL 37705603A PL 377056 A1 PL377056 A1 PL 377056A1
Authority
PL
Poland
Prior art keywords
antitumoral compounds
new antitumoral
new
compounds
kahalalide
Prior art date
Application number
PL377056A
Other languages
Polish (pl)
Other versions
PL209129B1 (en
Inventor
Glynn Thomas Faircloth
Mariano Elices
Halina Sasak
Marin Pablo Manuel Aviles
Marchante Maria Del Carmen Cuevas
Original Assignee
Pharma Mar, S.A.U.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2002/004735 external-priority patent/WO2003033012A1/en
Priority claimed from GBGB0304367.6A external-priority patent/GB0304367D0/en
Priority claimed from GB0314725A external-priority patent/GB0314725D0/en
Application filed by Pharma Mar, S.A.U. filed Critical Pharma Mar, S.A.U.
Publication of PL377056A1 publication Critical patent/PL377056A1/en
Publication of PL209129B1 publication Critical patent/PL209129B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to new kahalalide antitumoral compounds, in particular to analogues of kahalalide F, useful as antitumoral, antiviral, antifungal agents and in the treatment of psoriasis.
PL377056A 2002-10-18 2003-10-20 New antitumoral compounds PL209129B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/GB2002/004735 WO2003033012A1 (en) 2001-10-19 2002-10-18 Kahalalide compounds for use in cancer therapy
GBGB0304367.6A GB0304367D0 (en) 2003-02-26 2003-02-26 Methods for treating psoriasis
GB0314725A GB0314725D0 (en) 2003-06-24 2003-06-24 New antitumoral compounds

Publications (2)

Publication Number Publication Date
PL377056A1 true PL377056A1 (en) 2006-01-23
PL209129B1 PL209129B1 (en) 2011-07-29

Family

ID=35276268

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377056A PL209129B1 (en) 2002-10-18 2003-10-20 New antitumoral compounds

Country Status (12)

Country Link
KR (2) KR101149095B1 (en)
AT (1) ATE490975T1 (en)
AU (1) AU2003285911B2 (en)
CY (1) CY1111319T1 (en)
DE (1) DE60335292D1 (en)
DK (1) DK1572726T3 (en)
HK (1) HK1082261A1 (en)
IL (1) IL167724A (en)
NO (1) NO333448B1 (en)
PL (1) PL209129B1 (en)
PT (1) PT1572726E (en)
SI (1) SI1572726T1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0321066D0 (en) * 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
GB0408958D0 (en) * 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9302046D0 (en) * 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
DK1330258T3 (en) * 2000-10-31 2006-05-22 Pharma Mar Sa Kahalalid F formulation
AU2002334203C1 (en) * 2001-10-19 2008-10-09 Pharma Mar, S.A. Kahalalide compounds for use in cancer therapy

Also Published As

Publication number Publication date
PT1572726E (en) 2011-02-14
KR101149095B1 (en) 2012-05-30
AU2003285911A1 (en) 2004-05-04
KR20050070056A (en) 2005-07-05
SI1572726T1 (en) 2011-04-29
DE60335292D1 (en) 2011-01-20
PL209129B1 (en) 2011-07-29
CY1111319T1 (en) 2015-08-05
DK1572726T3 (en) 2011-03-28
ATE490975T1 (en) 2010-12-15
NO20052379L (en) 2005-07-15
NO333448B1 (en) 2013-06-10
HK1082261A1 (en) 2006-06-02
AU2003285911B2 (en) 2009-11-19
KR20110114690A (en) 2011-10-19
NO20052379D0 (en) 2005-05-13
IL167724A (en) 2012-01-31

Similar Documents

Publication Publication Date Title
HK1091112A1 (en) Compounds and methods for increasing neurogenesis
MX349188B (en) Sns-595 and methods of using the same.
MXPA02011288A (en) Substituted thioacetamides.
MXPA04003796A (en) Substituted thioacetamides.
GB0225474D0 (en) Therapeutic agents
HK1085140A1 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
TW200505434A (en) Therapeutic treatment
MY126527A (en) Novel dihydropyrimidines
MXPA04002593A (en) Compositions and methods for the diagnosis and treatment of tumor.
MXPA03011985A (en) Compositions and methods for the diagnosis and treatment of tumor.
MY135233A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
ATE320457T1 (en) POLYURETHANE SOLUTIONS WITH ALKOXYSIL STRUCTURAL UNITS
WO2003104443A3 (en) Hair follicle mesenchymal stem cells and use thereof
PL356846A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
GB0111186D0 (en) Novel compounds
WO2003099266A3 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
PL374080A1 (en) Processes for the preparation of fibrinogen
EP1667685A4 (en) Quinazoline potassium channel inhibitors
MXPA05004133A (en) 4-methylhexanoic kahalaide f compound.
EP1546182A4 (en) Compositions and methods for the diagnosis and treatment of tumor
IL135825A0 (en) Use of mirtazapine for treating sleep apneas
EP1667976A4 (en) Isoquinolinone potassium channel inhibitors
GB0326633D0 (en) Therapeutic agents
HK1082261A1 (en) 4-methylhexanoic kahalalide f compound
MXPA03004539A (en) Isolated luciferases and the use thereof.